Patent US4219877A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5079006A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical compositions containing a magnetically detectable material

Assignee: Aprex Corp
•
Filing: 1988-07-13
•
Granted: 1992-01-07
•
Expires: 2008-07-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical preparation is provided for oral or anal administration containing, in addition to a selected pharmacologically active agent, at least one magnetic material capable of reacting to an externally acting magnetic field of an electronic monitoring device, so that after administration to a patient, a signal is produced that is selectively detectable by such a monitoring device, thus providing information on whether the preparation has been taken or not by the patient and/or facilitates locating the preparation or the magnetic material in the region of the gastrointestinal tract of the patient.

Inventors

  • 👤 John Urquhart

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 02:08
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5094; A61B; A61B5/00; A61B5/05; A61B5/0515; A61B5/06; A61B5/48; A61B5/4833; A61J; A61J3/00; A61J3/007; A61K9/20; A61K9/2072; A61J2200/00; A61J2200/30

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 188 words
A pharmaceutical composition in unit dosage form for administration to the gastrointesinal tract of a patient comprising a pharmacologically active agent and a magnetic material, said magnetic material, when present in the gastrointestinal tract of the patient, being capable of reacting to an externally applied magnetic field to produce a magnetic signal which is selectively detectable by an electronic monitoring device, and thereby providing verification that the composition is present in the patient's gastrointestinal tract and further providing an indication of the location of the composition in the patient's gastrointestinal tract, the magnetic material being a material which exists prior to administration of the composition to the patient's gastrointestinal tract in a first state which does not produce the selectivity detectable magnetic signal but which undergoes transformation in the gastrointestinal tract, as a result of the action of the gastrointestinal environment, to a second state which does produce the selectively detectable magnetic signal, the magnetic material being a wire, tape, strip or film which in the first state is folded into a magnetically undetectable configuration and which in its second state is unfolded into a magnetically detectable configuration.
Claim 2
Dependent Claim 188 words
A pharmaceutical composition in unit dosage form for administration to the gastrointesinal tract of a patient comprising a pharmacologically active agent and a magnetic material, said magnetic material, when present in the gastrointestinal tract of the patient, being capable of reacting to an externally applied magnetic field to produce a magnetic signal which is selectively detectable by an electronic monitoring device, and thereby providing verification that the composition is present in the patient's gastrointestinal tract and further providing an indication of the location of the composition in the patient's gastrointestinal tract, the magnetic material being a material which exists prior to administration of the composition to the patient's gastrointestinal tract in a first state which does not produce the selectivity detectable magnetic signal but which undergoes transformation in the gastrointestinal tract, as a result of the action of the gastrointestinal environment, to a second state which does produce the selectively detectable magnetic signal, the magnetic material being a wire, tape, strip or film which in the first state is folded into a magnetically undetectable configuration and which in its second state is unfolded into a magnetically detectable configuration.
Claim 3
Dependent Claim 15 words
The composition of claim 1 wherein said magnetic material is comprised of magnetically soft material.
Claim 4
Dependent Claim 15 words
The composition of claim 1 wherein said magnetic material is comprised of an amorphous material.
Claim 5
Dependent Claim 13 words
The composition of claim 3, wherein said amorphous material is an amorphous metal.
Claim 6
Dependent Claim 14 words
The composition of claim 1, wherein said amorphous material is an amorphous iron-silicate-boron-carbon compound.
Claim 7
Dependent Claim 14 words
The composition of claim 1, wherein said magnetic material is biologically inert and nontoxic.
Claim 8
Dependent Claim 35 words
The composition of claim 1, wherein said composition is in a unit dosage form selected from the group consisting of a pill, lozenge, tablet, capsule, film- or membrane-coated tablet or capsule, sugar-coated pill, and suppository.
Claim 9
Dependent Claim 20 words
The composition of claim 1, wherein said magnetic material is present in a layer which coats said pharmacologically active agent.
Claim 10
Dependent Claim 20 words
The composition of claim 1 wherein said magnetic material has a shape memory for its magnetically detectable second state configuration.
Claim 11
Dependent Claim 11 words
The composition of claim 9, wherein the shape memory is preadjustable.
Claim 12
Dependent Claim 22 words
The composition of claim 1 wherein said magnetic material is completely or partly enclosed in an envelope comprised of a biodegradable material.
Claim 13
Dependent Claim 23 words
The composition of claim 1, wherein said magnetic material and said pharmacologically active agent are contained within a capsule having segregated compartments therefor.
Claim 14
Dependent Claim 14 words
The composition of claim 1, wherein said magnetic material is disposed on a substrate.
Claim 15
Dependent Claim 15 words
The composition of claim 1, wherein said magnetic material is encapsulated in a water-swellable polymer.
Claim 16
Dependent Claim 91 words
A method of determining whether or not a patient has taken a gastrointestinal tract administered pharmaceutical composition unit dosage form of claim 1, comprising the steps of: subjecting said patient to an externally applied alternating magnetic field, selectively detecting the presence or absence of said magnetic signal, and relating the presence of said magnetic signal to the fact that the patient had taken the pharmaceutical composition unit dosage form and the absence of said magnetic signal to the fact that the patient had not taken the pharmaceutical composition unit dosage form.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-01-06 1995-07-08 1996-01-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-01-06 1999-07-08 2000-01-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-01-06 2003-07-08 2004-01-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag